Abbott Laboratories

acquires

Laralab

Quantum Partners exclusively advised LARALAB GmbH and its shareholders in the M&A process

Dr. Andreas Brinkrolf
Managing Partner

Dr. Andreas Brinkrolf

Andreas Brinkrolf verfügt über langjährige Corporate-Finance-Erfahrung und hat bereits mehrfach erfolgreiche Unternehmen gegründet.</p>
<p>Als Venture Manager und später als Geschäftsführer des Siemens Technology Accelerators war er für die externe Vermarktung von Siemens-Technologien durch Verkauf, Spin-off und Lizenzierung verantwortlich. Im Vordergrund standen Hochtechnologie-Projekte, z.B. in den Bereichen Sensorik, Neue Materialien und Software.</p>
<p>Als Gründer und Vorstand der Tiburon Partners AG investierte er in Internet- und Software-Firmen und begleitete einige der Unternehmen über den gesamten Lebenszyklus bis zum Exit. Er war verantwortlich für den späteren Verkauf der Tiburon Partners AG an eine börsennotierte Holding. Herr Brinkrolf war Mitgründer der Invoco Holding GmbH und hat diese bei der Entwicklung zu einem der führenden Anbieter von Outsourcing-Dienstleistungen in Deutschland begleitet. Im Jahr 2013 verantwortete er den Unternehmensverkauf an die Xerox Corporation. In den letzten Jahren hat Herr Brinkrolf über 50 Transaktionen – Erstinvestitionen, Kapitalerhöhungen und Verkäufe – begleitet.</p>
<p>An den Universitäten Bamberg und Aston (UK) hat er Betriebswirtschaft studiert und an der Universität St. Gallen (CH) promoviert.

Andreas Brinkrolf
Deal Partner
brinkrolf@quantum-partners.de
+49 89 414 144 355

Quantum Partners advises LARALAB GmbH and its shareholders on sale to Abbott Laboratories

Therapeutic approaches for structural heart procedures have advanced dramatically over the past decade and now represent a multi-billion-dollar market. At the same time, complex manual pre-procedural assessments and a fragmented software landscape slow down day-to-day clinical practice. Per case, outdated desktop tools and manual workups cause substantial time loss. Failed initial assessments often push decisions out by days to weeks, increase treatment costs, and delay clinical studies.

The Munich-based software start-up LARALAB addresses these bottlenecks with heart.ai, the first fully automated, cloud-based solution for pre-screening cardiac interventions, including automated segmentations, 4D imaging analysis, and configurable workflows. As only solution available, heart.ai can provide screening results immediately without any manual workup, delivering significant efficiency gains for both patient care and clinical trials.

As the result of a structured, international M&A process, LARALAB has chosen to combine with Abbott, one of the world’s leading providers of transcatheter and surgical heart valve solutions. Through this transaction, Abbott expands its offering along the cardiovascular care pathway with a best-in-class digital platform, while enabling LARALAB to accelerate the international rollout of heart.ai.

Quantum Partners acted as exclusive financial advisor to the shareholders of LARALAB GmbH on this transaction.

About LARALAB

LARALAB GmbH is a Munich-based software start-up specializing in AI-enabled solutions for cardiology diagnostics. With its heart.ai platform, the company has developed the first fully automated solution for pre-screening heart valve replacement procedures.

About Abbott Laboratories

Abbott is a US-based, publicly traded pharmaceutical company with over 100,000 employees worldwide. The company is one of the leading providers of structural heart therapies with a broad portfolio of transcatheter and surgical solutions.

About Quantum Partners

Quantum Partners GmbH is a specialised M&A advisor based in Munich. We support technology and growth companies in the sale and acquisition of businesses, as well as in raising growth capital.